AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03701139 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior capsulotomy
Description: After phacoemulsification with intraocular lens implantation, primary posterior capsulotomy will be performed to remove the primary posterior capsule opacification after posterior capsule polishing. A limited anterior vitrectomy will be performed if the anterior hyaloid surface is broken.
Study NCT03701139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser capsulotomy
Description: A routine phacoemulsification with intraocular lens implantation is performed. Then the Nd:YAG laser capsulotomy will be performed 1 month postoperative to remove the primary posterior capsule opacification.
Study NCT02558517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone discontinuation
Description: randomization
Study NCT02917135 — intervention group
Intervention type: DEVICE
Intervention: Angel® Catheter
Description: The Angel® Catheter is a retrievable inferior vena cava (IVC) filter attached to a multi-lumen central venous access (CVC) catheter. The device is designed to be placed at the bedside in the inferior vena cava, via the femoral vein, for the prevention of pulmonary embolism (PE) and for access to the central venous system.~The Angel® Catheter is intended for short-term (less than 30 days) vascular access via the femoral vein.
Study NCT01712126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan and Hydrochlorothiazide
Study NCT01712126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avalide
Study NCT02432326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
Study NCT01303029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+erlotinib+capecitabine
Description: Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: esomeprazole
Description: Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: omeprazole
Description: Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: pantoprazole
Description: Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: lansoprazole
Description: Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: rabeprazole
Description: Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: cimetidine
Description: Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: ranitidine
Description: Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: famotidine
Description: Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: nizatidine
Description: Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: niperotidine
Description: Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: roxatidine
Description: Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: ranitidine bismuth citrate
Description: Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: lafutidine
Description: Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: cimetidine combinations
Description: Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.
Study NCT02555852 — intervention group
Intervention type: DRUG
Intervention: famotidine combinations
Description: Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.
Study NCT02432326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI503
Description: The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
Study NCT02915666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin Combination
Description: Digoxin 0.25 mg PO daily will be given for 8-week cycles
Study NCT04662853 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gut microbiota determination from feces samples.
Description: Determination of the gut microbiota composition by 16S metagenomic and building of a mathematical model, on the basis of the colonoscopies results, able to classify patients without and with color-rectal cancer-related lessions. These latter will be also classified according to the type of lession.
Study NCT02915666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: dabrafenib 150mg PO twice daily for 8-week cycles
Study NCT02915666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: trametinib 2 mg PO daily for 8-week cycles
Study NCT04048486 — intervention group
Intervention type: OTHER
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy-to-use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.
Study NCT04048486 — intervention group
Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination
Study NCT04048486 — intervention group
Intervention type: OTHER
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires
Study NCT02422498 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Radiation therapy to the target tumor will be delivered with external beam radiation therapy. In metastatic cases where the intent is palliative, the dose of radiation will be 3750 cGy delivered in 15 daily fractions, 4-5 days a week. In locoregionally recurrent cases where the intent is to enhance locoregional control, the dose of radiation will be 5000 cGy delivered in 25 fractions, 4-5 days a week plus an optional 10-14 Gy boost to areas of gross tumor.
Study NCT02422498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin treatment should be initiated following study registration. The dose of cisplatin is established as 25 mg/m\^2 ivpb once a week (+ 3 days) for 1-2 weeks prior to radiation. The length of one cycle of Cisplatin is 21 days.
Study NCT02422498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Target Tumor
Description: Biopsy of the tumor to be irradiated will be performed. Fresh tissue specimens will be sent to the laboratory for performance of the MSK-HRR Assay.
Study NCT03308916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: transient elastography
Description: Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis
Study NCT03308916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Enhanced liver fibrosis test
Description: Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)
Study NCT03308916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Indirect serum markers of liver fibrosis
Description: Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT
Study NCT03308916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Direct serum markers of liver fibrosis
Description: Serum markers that reflect liver extracellular matrix turnover and -accumulation
Study NCT03308916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LiverTRAIL
Description: Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.
Study NCT03308916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cytokeratin 18
Description: Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)
Study NCT03308916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Omics markers
Description: Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies
Study NCT01122602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)
Description: Single dose of fast acting aspirin 2 x 325 mg = 650 mg total
Study NCT01122602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicyclic acid (Aspirin, BAYE4465)
Description: Single dose of regular aspirin 2 x 325 mg = 650 mg total
Study NCT01122602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets
Study NCT00732823 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - No device worn
Study NCT00732823 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs
Study NCT00752557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
Description: Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 1.0 mg/mL.
Study NCT00752557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
Description: Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 2.0 mg/mL.
Study NCT01172535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
Study NCT04021095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Head protection prototype device
Description: The proposed experimental HPPD uses biocompatible material using FDMÔNylon which has high fatigue resistance, chemical resistance with impact resistance and toughness which is free of powders. It is HSA unclassified as yet and the FDMONylon is not FDA approved yet.
Study NCT02368665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: - Daily oral administration for 8 weeks
Study NCT02368665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg, Candesartan cilexetil 16mg
Description: - Daily oral administration Amlodipine 5mg for 8 weeks
Study NCT02368665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 10mg, Candesartan cilexetil 16mg
Description: - After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks
Study NCT02008123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primidone
Description: Primidone is an antiepileptic used for the management of generalized tonic-clonic seizures and for the management of complex partial seizures. One of primidone's active metabolite is phenobarbital, which is a potent cytochrome P450 inducer. In this study, primidone will be used to induce CYP 1A2 in order to provide more efficient metabolism of clopidogrel to its active form
Study NCT02959593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VISIOR video goggles
Description: View commercially available content through the VISIOR video goggles continuously for thirty minutes.
Study NCT02486575 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-learning
Description: Every resident will train following the video instruction included in the FLS course material and related written instruction only
Study NCT02486575 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mentoring
Description: A tutor will follow each resident during learning, giving instruction, examples and any kind of suggestions.
Study NCT03568981 — intervention group
Intervention type: RADIATION
Intervention: Partial breast irradiation
Description: After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
Study NCT03568981 — intervention group
Intervention type: RADIATION
Intervention: Whole breast irradiation
Description: After breast- conservating surgery, all patients are allowed to receive partial breast irradiation or whole breast irradiation after surgery according to the international guidelines and physician's discretion.
Study NCT00752557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bisphosphonates, calcium, and vitamin D
Description: Oral bisphosphonate therapy
Study NCT04072692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid rehabilitation training
Description: Hybrid rehabilitation training is modified tendon gliding exercise with median nerve mobilization.
Study NCT04072692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation training
Description: Traditional rehabilitation training uses traditional physiotherapy, such as splint, therapeutic ultrasound and electrotherapy.
Study NCT04072692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable anti-bowstringing orthosis (WABO)
Description: WABO is a custom-designed orthosis to restrict the bowstringing effect of the flexor tendon in the carpal tunnel.
Study NCT00105911 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Study NCT01156480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
Study NCT01156480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
Study NCT03573687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar Casein Protein
Description: The micellar casein protein supplement (PRO, total protein content: 30 g, 120 kcals; 30 g micellar protein) and non-caloric sensory-matched placebo (PLA, 0kcals) will be specifically formulated by Dymatize® Nutrition FrieslandCampina® and consumed in a randomized order. Participants will consume the daytime supplement 30 minutes after RT and the nighttime supplement about 30 minutes before bedtime. The supplements will be premixed, taste-matched (chocolate), and provided in opaque shaker bottles.
Study NCT03573687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: Resistance exercise training (RT) will target the full body and exercises will be performed using a barbell. Exercises will be performed in the following order: back squat, bench press, Romanian deadlift, bent-over row, shoulder press, and reverse lunges)
Study NCT00887302 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric Band
Description: Places a band over the upper portion of the stomach.
Study NCT00887302 — intervention group
Intervention type: PROCEDURE
Intervention: Gastric Sleeve
Description: Stapling stomach vertically to reduce size of stomach and removal of larger curve portion of the stomach
Study NCT00887302 — intervention group
Intervention type: PROCEDURE
Intervention: Gastrostomy Tube
Description: Tube is inserted into the stomach that delivers nutrition directly into the stomach.
Study NCT02470221 — intervention group
Intervention type: OTHER
Intervention: Applying goal-directed fluid therapy by continuous hemodynamic monitoring system
Description: Applying continuous hemodynamic monitoring system ( Vigileo/Flotrac) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
Study NCT02470221 — intervention group
Intervention type: OTHER
Intervention: Conventional fluid therapy
Description: Applying conventional fluid therapy according to Peking Union Medical College Hospital standard.
Study NCT02289664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAC
Description: Direct-Laryngoscopy
Study NCT03935321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG-101
Description: 6 intrathecal bolus injections, each of 45mg
Study NCT02289664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coopdech
Description: Video-Laryngoscopy -1
Study NCT02289664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoPilot
Description: Video-Laryngoscopy -2
Study NCT02289664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubrite
Description: Video-Laryngoscopy -3
Study NCT04537793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed dose combination granules for oral administration.
Study NCT04537793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Granules for oral administration.
Study NCT02976337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: active drug infusion
Study NCT02976337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: placebo comparator
Study NCT02859246 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mucinex®
Description: Mucinex®
Study NCT02271464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance:BEVACIZUMAB
Description: Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:~* BEVACIZUMAB 5 mg/kg over 30 minutes, day 1~* IRINOTECAN 165 mg/sqm IV over 1-h, day 1~* OXALIPLATIN 85 mg/sqm IV over 2-h, day 1~* L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1~* 5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1~with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):~- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)